Pediatric poisoning from trimedoxime (TMB4) and atropine automatic injectors
Eran Kozer1, Amnon Mordel, Shmuael Bar Haim
1Sakler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. erank@asaf.health.gov.il
Insights
Unintentional pediatric injection of atropine and trimedoxime (TMB4) via automatic injectors rarely causes significant side effects, even with adult doses in children. Most side effects were mild and related to atropine.
Area of Science:
- Pediatric Toxicology
- Emergency Medicine
- Pharmacology
Background:
- Automatic injectors (AIs) containing atropine and trimedoxime (TMB4) are used for treating nerve agent exposure.
- Accidental pediatric exposure to these AIs can occur, necessitating an understanding of potential adverse effects.
Purpose of the Study:
- To investigate the clinical effects and safety profile of unintentional pediatric exposure to combined atropine and TMB4 from automatic injectors.
Main Methods:
- Retrospective data collection from the Israel Poison Information Center and pediatric emergency departments.
- Analysis of demographic data, AI type, injection details, and clinical manifestations in 142 pediatric patients.
Main Results:
- Most patients received age-appropriate doses; however, 15.5% received higher doses.
- Mild atropine-related side effects observed included dilated pupils, dry mucous membranes, and tachycardia.
- Children receiving higher doses were more likely to be symptomatic (P = .029).
- No significant side effects were attributed to TMB4, and no specific medical intervention was required.
Conclusions:
- Unintentional pediatric exposure to atropine and TMB4 via AIs, even at adult doses, is generally safe.
- The observed side effects are typically mild and transient, primarily linked to atropine.
Objective:
To describe the effects of combined trimedoxime (TMB4) and atropine poisoning from automatic injectors (AI) in children.
Study Design:
Data was collected from two sources: calls to the Israel Poison Information Center (IPIC) during a 1-year period and a cohort of children who presented to pediatric emergency departments (EDs) after unintentional injection of an AI. Demographic data and data regarding the type of AI, site and time of injection, and the clinical manifestations were abstracted.
Results:
Data were available for 142 patients. The median age was 8.5 years (range 1.25-18 years). The dose of atropine and TMB4 was higher than the recommended dose for age in 22 (15.5%) cases. There were few side effects attributable to atropine: dilated pupils (26.7%), dryness of mucous membranes (24.6%), and tachycardia (22.5%). Compared with children injected with an age-appropriate dose, children injected with an AI that contained a dose that exceeds the recommended one were more likely to be symptomatic ( P = .029). There were no side effects characteristic to oximes, and no specific medical intervention was required.
Conclusions:
Unintentional pediatric atropine and TMB4 injection, even an adult dose in a small child, does not cause significant side effects.
Related Concept Videos
Prevention of Further Absorption of Poison
Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical Poisoning: Treatment Strategies
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Toxidromes: Clinical Features
Antidotes
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...


